Endometriosis Market Analysis, Epidemiology, and Forecast Through 2034

DelveInsight's comprehensive "Endometriosis Market Insights, Epidemiology, and Market Forecast-2034" analysis delivers extensive understanding of Endometriosis, historical and projected epidemiology alongside market trends across the United States, EU4 nations (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Explore Endometriosis market patterns, treatment landscapes, and emerging therapeutic agents shaping the future. Access sample analysis @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Major Highlights from the Endometriosis Market Analysis

• During December 2025, Gesynta Pharma AB performed a Phase 2 clinical investigation to evaluate the Efficacy and Safety of 2 Doses of Vipoglanstat in Patients Diagnosed With Moderate to Severe Endometriosis-related Pain - the NOVA Trial

• The Endometriosis market dimension was estimated at approximately USD 2,300 million in 2023 and is projected to expand with substantial CAGR throughout the analysis timeframe (2020-2034).

• Among the total endometriosis market dimension across the 7MM, the United States maintained the largest share, reaching approximately USD 1,400 million in 2023.

• During 2023, the UK maintained the largest market share at approximately 20% within the EU4 and UK region, while Spain demonstrated the smallest share.

• During 2023, there were approximately 10.8 million diagnosed prevalent cases of endometriosis across the 7MM, with the highest number documented in the United States.

• Endometriosis is most prevalent among females aged 18-29, representing approximately 40% of all cases in the 7MM.

• During 2023, the total number of treated endometriosis cases was approximately 2.9 million in the US, followed by the UK and France.

• According to the findings of Yoshino et al. (2022), approximately 2.6 million women in Japan are affected by endometriosis.

• Leading Endometriosis pharmaceutical organizations include AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, among others

• Notable Endometriosis investigational agents include ORILISSA (elagolix), MYFEMBREE (relugolix, estradiol, and norethindrone acetate), ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), Leuprolide Oral Tablet, SN132D, OG-6219, Elagolix, Relugolix, HMI-115, Quinagolide 1080 μg, OBE2109, SASHR7280, Estradiol/Norethindrone Acetate, TAK-385, NBI-56418 (GnRH antagonist), KLH-2109, Dienogest (Visanne, BAY86-5258), ERB-041, among others

Strategize your business objectives by comprehending market dynamics @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Endometriosis Disease Background

Endometriosis represents a chronic condition in which tissue similar to the lining of the uterus (endometrium) develops outside the uterus, commonly on the ovaries, fallopian tubes, or pelvic lining. This misplaced tissue behaves like normal endometrial tissue—thickening, breaking down, and bleeding with each menstrual cycle—but has no mechanism to exit the body, resulting in inflammation, pain, and scar tissue formation. Symptoms frequently encompass pelvic pain, painful periods, infertility, and digestive complications. While there is no cure, treatment alternatives including hormonal therapy, pain relievers, and surgery can facilitate symptom management and improve quality of life.

Endometriosis Epidemiology Analysis

The epidemiology segment delivers insights into historical, current, and projected epidemiology patterns across the seven major countries (7MM) from 2020 through 2034. It facilitates recognition of causes underlying current and forecasted patterns by examining multiple studies and perspectives of key opinion leaders. The epidemiology segment additionally provides comprehensive analysis of the diagnosed patient population and emerging trends.

Endometriosis Epidemiology Classification:

The Endometriosis market analysis presents epidemiological evaluation for the analysis period 2020-2034 across the 7MM categorized into:

• Total Prevalence of Endometriosis

• Prevalent Cases of Endometriosis by severity classification

• Gender-specific Prevalence of Endometriosis

• Diagnosed Cases of Episodic and Chronic Endometriosis

Access additional information about Endometriosis Prevalence @  https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Endometriosis Drug Adoption and Pipeline Activities

The drug adoption segment concentrates on the uptake velocity of potential therapeutic agents recently introduced in the Endometriosis marketplace or anticipated to launch during the analysis period. The evaluation encompasses Endometriosis market adoption by drugs, patient adoption by treatment modalities, and revenue of individual drugs. Furthermore, the therapeutics evaluation segment facilitates understanding of drugs demonstrating the most accelerated adoption and underlying reasons for maximal utilization. Additionally, it compares therapeutic agents based on market penetration. The analysis also encompasses the Endometriosis Pipeline Development Activities. It delivers valuable insights regarding various therapeutic candidates across multiple phases and primary organizations engaged in developing targeted therapies. It additionally analyzes recent advancements including collaborations, acquisitions, mergers, licensing patent information, and other intelligence for emerging therapeutic agents.

Endometriosis Therapeutic Agents and Leading Organizations

• ORILISSA (elagolix): AbbVie

• MYFEMBREE (relugolix, estradiol, and norethindrone acetate): Myovant/Pfizer

• ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences

• Linzagolix (OBE2109): ObsEva/Kissei Pharmaceutical

• Leuprolide Oral Tablet: Enteris BioPharma Inc.

• SN132D: Spago Nanomedical AB

• OG-6219: Iqvia Pty Ltd

• Elagolix: Nanjing Chia-tai Tianqing Pharmaceutical

• Relugolix: Myovant Sciences GmbH

• HMI-115: Hope Medicine (Nanjing) Co., Ltd

• Quinagolide 1080 μg: Ferring Pharmaceuticals

• OBE2109: ObsEva

• SASHR7280: Jiangsu HengRui Medicine

• Estradiol/Norethindrone Acetate: AbbVie

• TAK-385: ASKA Pharmaceutical Co., Ltd.

• NBI-56418 (GnRH antagonist): Abbott

• KLH-2109: Kissei Pharmaceutical Co., Ltd.

• Dienogest (Visanne, BAY86-5258): Bayer

• ERB-041: Pfizer

For additional information, access Endometriosis Medication and Companies @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Endometriosis Market Strengths

• The increasing prevalence of endometriosis represents the primary strength of its global marketplace, resulting in greater focus by pharmaceutical organizations

• At national and international levels, government and key market players actively invest in research and development initiatives and increase funding, further supporting market expansion.

Endometriosis Market Opportunities

• Industry leaders are partnering with healthcare providers to enhance awareness in the field of endometriosis at both physician and patient levels

• Novel diagnostic tools and techniques or methodologies can be explored for early detection of endometriosis in the affected patient population

Coverage of the Endometriosis Market Analysis

• Analysis Period: 2020-2034

• Coverage: 7MM

• Leading Endometriosis Pharmaceutical Organizations: AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, among others

• Primary Endometriosis Therapeutic Agents: ORILISSA (elagolix), MYFEMBREE (relugolix, estradiol, and norethindrone acetate), ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), Leuprolide Oral Tablet, SN132D, OG-6219, Elagolix, Relugolix, HMI-115, Quinagolide 1080 μg, OBE2109, SASHR7280, Estradiol/Norethindrone Acetate, TAK-385, NBI-56418 (GnRH antagonist), KLH-2109, Dienogest (Visanne, BAY86-5258), ERB-041, among others

• Endometriosis Therapeutic Evaluation: Endometriosis current commercialized and Endometriosis investigational therapies

• Endometriosis Market Dynamics: Endometriosis market growth factors and Endometriosis market obstacles

• Competitive Intelligence Evaluation: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry methodologies

• Endometriosis Unmet Requirements, KOL perspectives, Analyst perspectives, Endometriosis Market Access and Reimbursement

Do you know the treatment paradigms for various countries? Access our Endometriosis Treatment Market @ https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=sites&utm_medium=promotion&utm_campaign=kkpr

Report Structure

1. Endometriosis Market Analysis Introduction

2. Executive Summary for Endometriosis

3. SWOT evaluation of Endometriosis

4. Endometriosis Patient Distribution (%) Overview at a Glance

5. Endometriosis Market Overview at a Glance

6. Endometriosis Disease Background and Overview

7. Endometriosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Endometriosis

9. Endometriosis Current Treatment and Medical Practices

10. Endometriosis Unmet Requirements

11. Endometriosis Emerging Therapeutic Agents

12. Endometriosis Market Perspective

13. Country-Wise Endometriosis Market Evaluation (2020-2034)

14. Endometriosis Market Access and Reimbursement of Therapeutic Agents

15. Endometriosis Market Growth Factors

16. Endometriosis Market Obstacles

17. Endometriosis Appendix

18. Endometriosis Analysis Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a prominent healthcare-focused market research and consulting organization that delivers clients with premium market intelligence and analysis to facilitate informed business decisions. With a team of seasoned industry specialists and comprehensive understanding of the life sciences and healthcare industries, we provide customized research solutions and insights to clients worldwide. Connect with us to obtain high-quality, precise, and real-time intelligence to maintain a competitive advantage.

Contact Us 

Kanishk

kkumar@delveinsight.com